September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when compared to paclitaxel-eluting stents.

September 24, 2010 - The New England Journal of Medicine has published the results of from a trial looking at the treatment of severe aortic stenosis. The results from cohort B of the Partner trial, which studied the Edwards Sapien transcatheter heart valve, successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.

September 23, 2010 – The U.S. Food and Drug Administration (FDA) has conditionally approved the first part of a trial testing a new transcatheter heart valve.

September 23, 2010 – The United States District Court for the District of New Hampshire entered a permanent injunction in a patent infringement lawsuit between two medical device companies.

September 23, 2010 - The first-in-human procedure to use ultrasound therapy to treat mitral regurgitation (MR) has been successfully completed. The data from the study, which used ReCor Medical’s ultrasound therapy, will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting in Washington, D.C.

September 22, 2010 – Coronary artery disease, a leading cause of death and poor quality of life worldwide, can often complicate the daily practice of interventional cardiology. But new data from an international “all comers” study demonstrate that Medtronic’s Resolute drug-eluting stent (DES) can help patients across the disease continuum, from simple to complex.

September 22, 2010 – Trial data indicate that a new stent may be a safer solution to treat heart attack patients. The Apposition II study found that the Stentys self-apposing stent helps reduce the risk of malapposition in patients who have suffered an acute myocardial infarction (AMI).

September 21, 2010 – A new drug-eluting stent system has received CE mark approval for diabetic patients and those experiencing a heart attack. The PROMUS element everolimus-eluting stent system, made by Boston Scientific, can be used in patients with concomitant diabetes mellitus as well as those suffering from an acute myocardial infarction (AMI).